GSK (GLAXF) Other Operating Expense: $-1,992 Mil (TTM As of Mar. 2026)


GLAXF GSK PLC GLAXF
75 GF Score
Price $25.12
GF Value $21.13
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK Other Operating Expense?

GSK GLAXF -0.85% 75 Other Operating Expense is $-1,992 Mil as of Mar. 2026. GuruFocus rates GLAXF with a GF Score™ of 75/100 and a GF Value™ of $21.13 (Modestly Overvalued). The stock has 1 warning sign investors should review.

GSK's Other Operating Expense for the three months ended in Mar. 2026 was $-467 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-1,992 Mil.

GSK's quarterly Other Operating Expense declined from Sep. 2025 ($-314 Mil) to Dec. 2025 ($-715 Mil) but then increased from Dec. 2025 ($-715 Mil) to Mar. 2026 ($-467 Mil).

GSK's annual Other Operating Expense increased from Dec. 2023 ($-1,506 Mil) to Dec. 2024 ($-796 Mil) but then declined from Dec. 2024 ($-796 Mil) to Dec. 2025 ($-1,742 Mil).

GSK Other Operating Expense Historical Data

* Premium members only.

The historical data trend for GSK's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Other Operating Expense Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -577.13 -997.56 -1,506.33 -796.46 -1,741.63

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -218.35 -496.61 -313.51 -714.86 -466.67
GLAXF
75GF Score
GSK PLC GLAXF
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,992 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-1,992 Mil mean?
GSK (GLAXF) has a Other Operating Expense of $-1,992 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on GSK and its competitors.
Is GSK's Other Operating Expense too high?
GSK's current Other Operating Expense is $-1,992 Mil. Overall, GSK has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Other Operating Expense compare to LLY and JNJ?
GSK's Other Operating Expense of $-1,992 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on GSK and its competitors. GSK's current Other Operating Expense is $-1,992 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.13, compared to a current price of $25.12 — trading 18.9% above its estimated fair value. The current Other Operating Expense is $-1,992 Mil. GSK's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For GSK (GLAXF), the current Other Operating Expense is $-1,992 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (GLAXF) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of $25.12 is trading 18.9% above its estimated GF Value™ of $21.13. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for GLAXF:

  • Other Operating Expense: $-1,992 Mil
  • GF Value™: $21.13 vs. price of $25.12 (18.9% above fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score

Get the complete analysis for GLAXF

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.12
Price
$21.13
GF Value